Pinealon

Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR peptide), developed within the Russian peptide bioregulator program as a minimal active sequence derived from pineal peptide preparations EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. It is studied mainly for neuroprotection and cognitive effects, not as an acute receptor activator Effects of short peptides on the molecular mechanisms of aging in laboratory primates+1.

A tripeptide means it is made of just three amino acids. Most Pinealon research comes from cell models and animal studies, with only limited human reporting EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. The strongest preclinical findings involve neuronal survival, dendrite structure, and antioxidant activity Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes+2.

Research uses span age-related cognitive decline, Alzheimer's disease, Huntington's disease, diabetic cognitive impairment, and stress-related hypothalamic dysregulation EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease+3.

Pinealon's primary action is transcriptional rather than acute receptor activation. It can enter the cell nucleus, bind DNA and histone proteins, and shift gene expression toward neuroprotection, antioxidant defense, and synaptic maintenance Effects of short peptides on the molecular mechanisms of aging in laboratory primates+1.

In biophysical work, EDR binds the DNA major groove with preference for guanine N7 and O6 atoms, and magnesium promotes the interaction Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. Downstream, the peptide is proposed to influence MAPK/ERK signaling and the expression of proteins linked to cell survival, antioxidant enzymes, serotonin, and calmodulin EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

Secondary mechanisms from animal and cell data:

• Antioxidant and hypoxic defense: protects brain neurons from hypoxia in vivo Regulatory peptides protect brain neurons from hypoxia in vivo+1 and reduces oxidative DNA damage in human induced neurons Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.
• Synaptic plasticity: improves learning and changes NMDA receptor subunit gene expression in diabetic rats Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes.
• Neuroendocrine regulation: corrects disrupted diurnal hypothalamic norepinephrine dynamics in female rats Pinealon corrects hyperhomocysteinemia-induced disturbances of the diurnal dynamics of hypothalamic norepinephrine content in female rats. In aged primates, the short pineal peptides Epithalamin/Epitalon normalized melatonin/cortisol rhythms Effects of short peptides on the molecular mechanisms of aging in laboratory primates, while Pinealon improved cognitive function and restored neuroimmunoendocrine balance Effects of short peptides on the molecular mechanisms of aging in laboratory primates.

Pinealon's documented effects are mostly preclinical, with stronger mechanistic support than human efficacy data.

• Cell models: increased dendritic processes and dendrite length in induced neurons from aged donors, plus reduced oxidative DNA damage Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.
• Huntington's disease model: restored dendritic spine morphology in striatal neurons Neuroprotective Effect of EDR Peptide in Mouse Model of Huntington's Disease.
• Diabetic cognitive impairment: improved learning and altered hippocampal NMDA receptor subunit expression in rats Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes.
• Stress-related circadian disruption: normalized hypothalamic norepinephrine daily rhythms in rats Pinealon corrects hyperhomocysteinemia-induced disturbances of the diurnal dynamics of hypothalamic norepinephrine content in female rats.
• Aged primates: course administration was associated with improved cognitive function and restored neuroimmunoendocrine balance Effects of short peptides on the molecular mechanisms of aging in laboratory primates.
• Human data: limited to review-level statements of memory improvement in elderly patients, with low methodological clarity EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

No human randomized controlled trial defines a Pinealon dose. The strongest evidence comes from rodent, primate, and cell models, often with course-based parenteral administration and unstandardized doses Effects of short peptides on the molecular mechanisms of aging in laboratory primates+3.

Community and practitioner protocols generally describe 50 to 200 mcg subcutaneous or 100 to 500 mcg intranasal once daily for 10 to 20 days, followed by a rest period. Some protocols use 5 days on and 2 days off over 6 to 8 weeks. No formal dose-response curve has been established.

Timing is not standardized. Because animal data show Pinealon normalizes diurnal norepinephrine rhythms Pinealon corrects hyperhomocysteinemia-induced disturbances of the diurnal dynamics of hypothalamic norepinephrine content in female rats, community practice tends toward morning or early afternoon administration. The interactive timeline below shows one representative course pattern, not an evidence-based prescription.

No Pinealon-specific reconstitution studies exist. Standard aseptic handling for lyophilized peptides is used in community protocols.

Use bacteriostatic water for multi-dose vials and sterile water for injection for single-use supplies. Add diluent slowly down the vial wall and swirl gently, rather than shaking, to avoid foaming.

Storage guidance:

• Lyophilized powder: store at -20°C for long term or 2 to 8°C for short term, protected from light and moisture.
• After reconstitution: keep at 2 to 8°C; do not refreeze.
• With bacteriostatic water: discard after 14 days.
• With sterile water: discard after 24 to 48 hours.

Use the calculator below to determine specific volume and concentration for a given vial and dose.

No formal human drug interaction studies exist. All known interactions are inferred from Pinealon's preclinical mechanisms: DNA/histone binding EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease+1, modulation of p53, caspase-3, PPAR, serotonin and calmodulin EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease, neuronal NMDA receptor expression Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes, and norepinephrine normalization Pinealon corrects hyperhomocysteinemia-induced disturbances of the diurnal dynamics of hypothalamic norepinephrine content in female rats.

Potential interactions by class:

• Cognition drugs such as cholinesterase inhibitors and memantine may add to pro-cognitive effects, though no dose-adjustment data exist Effects of short peptides on the molecular mechanisms of aging in laboratory primates+1.
• Serotonergic drugs including SSRIs, SNRIs, 5-HTP, and St. John's Wort carry a theoretical pharmacodynamic interaction through serotonin and calmodulin signaling EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.
• Blood pressure medicines could interact because Pinealon normalizes hypothalamic norepinephrine patterns Pinealon corrects hyperhomocysteinemia-induced disturbances of the diurnal dynamics of hypothalamic norepinephrine content in female rats.
• Antidiabetic agents have unknown interaction risk; diabetic rat data show NMDA expression changes and learning improvement, but no human glucose data Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes.
• DNA-damaging treatments: EDR interacts with the DNA major groove and modulates p53 and caspase-3, so caution is appropriate with active chemotherapy or radiotherapy EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease+1.

Pinealon is usually cycled as a course rather than taken continuously. Community protocols commonly use 10 to 20 days on, followed by 2 to 4 weeks off. Some protocols use 5 days on and 2 days off for 6 to 8 weeks, then a 4-week break. No randomized controlled trial defines an optimal cycle.

The rationale is transcriptional. Because Pinealon may regulate gene expression through DNA/histone interactions, its cellular effects may outlast plasma clearance, so continuous daily use is not assumed to be necessary EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease+1. Animal research also uses course-based administration rather than continuous dosing Effects of short peptides on the molecular mechanisms of aging in laboratory primates+2.

No formal tolerance has been demonstrated, but repeated transcriptional stimulation tends to favor rest periods. If cognitive benefit plateaus or side effects such as headache or sleep fragmentation appear, research monitoring guides often suggest a break of at least 2 weeks before reinitiating.

Pinealon is commonly discussed alongside other short peptide bioregulators, especially Epithalon. Epithalon is Ala-Glu-Asp-Gly (AEDG), a different peptide with pineal and antioxidant research emphasis, while Pinealon is Glu-Asp-Arg Effects of short peptides on the molecular mechanisms of aging in laboratory primates+2. No head-to-head data exist.

Other combinations from community protocols:

• Semax / Selank: different mechanisms; no formal interaction data, but sometimes combined for nootropic effects.
• Cerebrolysin / Cortexin: neurotrophic peptides that may overlap with Pinealon's gene-regulatory and antioxidant effects Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes+1.
• BPC-157 / TB-500: no shared pathways identified; some community stacks include them for tissue healing.
• Growth hormone secretagogues such as CJC-1295 or ipamorelin: no known direct interaction, but blood pressure may deserve monitoring due to Pinealon's norepinephrine-normalizing effect Pinealon corrects hyperhomocysteinemia-induced disturbances of the diurnal dynamics of hypothalamic norepinephrine content in female rats.

No FDA or EMA approval is identified in the reviewed corpus EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Pinealon is not listed in the Controlled Substances Act and is not a DEA-scheduled substance. It is primarily available through research chemical vendors and peptide clinics, not as an approved drug.

In sports, Pinealon is not explicitly named on the WADA Prohibited List in the reviewed sources. However, because it lacks regulatory approval as a human therapeutic, WADA's S0 category for non-approved substances applies. This means Pinealon is prohibited at all times for athletes under WADA Code compliance.

International status is similar: no EMA, TGA, or MHRA marketing authorization is documented.

Pinealon has no formal human adverse-event database. Preclinical and limited human reports have not identified serious adverse events at tested microgram doses Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes+1. Community reports rarely describe transient injection-site redness or stinging after subcutaneous use, and mild nasal irritation after intranasal use.

Because Pinealon binds DNA grooves and histones, theoretical risks include:

• Epigenetic drift: long-term repeated exposure could alter gene regulation, but no human carcinogenicity or mutagenicity data exist EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease+1.
• Cancer interaction: DNA binding and modulation of p53 and caspase-3 raise caution for use in active malignancy or with DNA-damaging therapies EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease+1.
• Seizure threshold: NMDA receptor subunit changes in diabetic rats Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes make excitability a theoretical concern, though no seizures were reported.
• Pregnancy and lactation: no reproductive safety studies exist, so use is generally avoided.
• Autoimmune conditions and severe kidney or liver impairment: unstudied peptide clearance and potential immune or gene modulation warrant caution.